ARCT - CONSENSUS CO - Arcturus Therapeutics

The share price retrospective for Arcturus Therapeutics (ARCT) demonstrates the dynamics of an asset with a market valuation of 23.13. Arcturus Therapeutics (ARCT) relies on cutting-edge mRNA developments and its unique LUNAR delivery system. Business growth is driven by the partnership with CSL and the success of liver therapy trials. Currently, breakthrough vaccines and medicines are transitioning to the stage of mass global sales.

Market expectations for Arcturus Therapeutics (ARCT) often fluctuate between speculative optimism and the fundamental value of assets. The average analyst target, which has reached 23.13, represents an aggregated assessment of the stock's fair value. The dynamics of the market target consensus visualize expert reactions to financial reports. For Arcturus Therapeutics, this indicator relies on the potential of the LUNAR platform. Licensing revenues from pharma behemoths stabilize this forecast, reducing valuation volatility.